Evidence map›Paper›PMID 41965734›Full record

ArticleBreast cancer research : BCR2026

A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.

Kayla M Switalla, Natsuko Onishi, Ella F Jones, Courtney Lawhn-Heath, Kimberly M Ray, Deep K Hathi, Julia C Carmona-Bozo, Pouya Metanat, Alexandra J Lopes, Israel O Falade and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kayla M SwitallaDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Natsuko OnishiDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Ella F JonesDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Courtney Lawhn-HeathDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Kimberly M RayDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Deep K HathiDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Julia C Carmona-BozoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Pouya MetanatDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Alexandra J LopesSchool of Medicine, University of California San Francisco, San Francisco, CA, USA.
Israel O FaladeDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Astrid QuirarteDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Soumya GottipatiDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Ruby GuoDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Julissa Molina-VegaDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Kami PullakhandamDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Teffany Joy BarengDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Margarita WatkinsDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
A Jo ChienDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Bonnie N Joe
Laura J EssermanDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Nola HyltonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Rita A MukhtarDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA. Rita.Mukhtar@ucsf.edu.

Funding

Dedicated breast PET and MRI for characterization of breast cancer and its response to therapyR01CA227763 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Natsuko Onishi Yamashita · 2019 to 2026
$3.6M
Identifying responders to chemotherapy in invasive lobular carcinoma of the breast: development of a multivariable clinical prediction toolK08CA256047 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUKHTAR, RITA · 2021 to 2025
$1.3M
NCI NIH HHS K08CA256047NCI NIH HHS R01 CA227763NIH HHS R01 CA227763U.S. Department of Defense A81XWH-18-1-0671
6 · The paper itself

Abstract

purposeInvasive lobular carcinoma (ILC) of the breast presents challenges in monitoring response to neoadjuvant endocrine therapy (NET). Dedicated breast positron emission tomography with 18F-fluoroestradiol (FES-dbPET), a molecular imaging technique targeting the estrogen receptor (ER), may offer insight into treatment response. This study evaluated whether changes in FES-dbPET uptake before and after NET in patients with ILC correlate with treatment response indicators, and whether these associations differ by endocrine therapy type.

methodsThis prospective pilot study included patients with stage I-III ER positive, human epidermal growth factor 2 (HER2) negative ILC undergoing NET between 2017 and 2021. FES-dbPET was performed pre- and post-NET. Patients were stratified by type of NET received – aromatase inhibitor (AI) therapy or selective estrogen receptor modulator/degrader (SERM/SERD) therapy. The primary goal was to assess correlation between FES-dbPET parameters and change in tumor Ki-67 staining (%), a validated prognostic endpoint after NET.

resultsWe enrolled 19 patients with ER + HER2- ILC, of whom 12 underwent both pre- and post-NET FES-dbPET. Among the AI cohort, changes in SUVpk and SULpk from pre- to post-NET each positively correlated with changes in Ki-67, though these associations did not reach statistical significance (r = 0.74, p = 0.256; and r = 0.75, p = 0.254, respectively). Conversely, among the SERM/SERD cohort, changes in SUVpk and SULpk strongly and positively correlated with changes in Ki-67 (r = 0.92, p = 0.027; and r = 0.92, p = 0.028, respectively).

conclusionIn this pilot study of 19 ER + ILC patients, change in FES uptake on dbPET showed some correlations with tumor response to NET. These findings suggest potential for FES-dbPET to capture tumor biology beyond that of standard imaging tools in predicting therapy response for patients with ILC. Further research with larger samples is needed to refine the role of FES-dbPET in improving neoadjuvant treatment monitoring and surgical planning in ILC patients.

Indexed as

Breast NeoplasmsCarcinoma, LobularEstradiolPositron-Emission TomographyAdultAgedAntineoplastic Agents, HormonalAromatase InhibitorsFemaleHumansMiddle AgedNeoadjuvant TherapyPilot ProjectsProspective StudiesReceptors, EstrogenAntineoplastic Agents, HormonalAromatase InhibitorsEstradiolReceptors, Estrogen18F-fluoroestradiol (FES)Dedicated breast PETILCNeoadjuvant endocrine therapy

Identifiers

PMID41965734
PMCPMC13185200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.